See more : BioVaxys Technology Corp. (BVAXF) Income Statement Analysis – Financial Results
Complete financial analysis of TransMedics Group, Inc. (TMDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TransMedics Group, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Telsys Ltd. (TLSY.TA) Income Statement Analysis – Financial Results
- Triton International Limited (TRTN) Income Statement Analysis – Financial Results
- PT Lautan Luas Tbk (LTLS.JK) Income Statement Analysis – Financial Results
- SKY Perfect JSAT Holdings Inc. (9412.T) Income Statement Analysis – Financial Results
- Maheshwari Logistics Limited (MAHESHWARI.NS) Income Statement Analysis – Financial Results
TransMedics Group, Inc. (TMDX)
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.69M | 6.21M |
| Cost of Revenue | 87.53M | 28.19M | 9.10M | 9.00M | 9.74M | 7.28M | 5.55M | 5.44M |
| Gross Profit | 154.09M | 65.27M | 21.16M | 16.64M | 13.86M | 5.73M | 2.14M | 766.00K |
| Gross Profit Ratio | 63.77% | 69.84% | 69.92% | 64.88% | 58.73% | 44.05% | 27.81% | 12.34% |
| Research & Development | 63.27M | 26.81M | 22.30M | 18.83M | 19.87M | 13.66M | 14.96M | 15.64M |
| General & Administrative | 119.55M | 51.69M | 38.28M | 24.19M | 21.52M | 12.32M | 7.61M | 0.00 |
| Selling & Marketing | 0.00 | 18.21M | 8.60M | 931.00K | 2.07M | 1.02M | 674.00K | 0.00 |
| SG&A | 119.55M | 69.90M | 38.28M | 24.19M | 23.60M | 12.32M | 7.61M | 8.12M |
| Other Expenses | 0.00 | -1.00M | -877.00K | 1.65M | 790.00K | -213.00K | 548.00K | 5.00K |
| Operating Expenses | 182.82M | 96.71M | 60.59M | 43.02M | 43.47M | 25.97M | 22.56M | 23.75M |
| Cost & Expenses | 270.35M | 124.90M | 69.69M | 52.02M | 53.21M | 33.25M | 28.11M | 29.20M |
| Interest Income | 12.50M | 900.00K | 100.00K | 700.00K | 1.00M | 0.00 | 548.00K | 5.00K |
| Interest Expense | 10.79M | 3.73M | 3.87M | 3.99M | 4.35M | 2.42M | 1.07M | 979.00K |
| Depreciation & Amortization | 8.18M | 4.20M | 2.65M | 1.58M | 1.22M | 769.00K | 630.00K | 426.00K |
| EBITDA | -7.60M | -28.96M | -38.49M | -23.15M | -27.93M | -20.23M | -19.09M | -22.66M |
| EBITDA Ratio | -3.15% | -34.71% | -133.19% | -96.46% | -122.07% | -151.19% | -250.46% | -363.26% |
| Operating Income | -28.73M | -31.44M | -39.43M | -26.38M | -29.60M | -20.24M | -20.43M | -22.99M |
| Operating Income Ratio | -11.89% | -33.64% | -130.29% | -102.91% | -125.42% | -155.47% | -265.79% | -370.20% |
| Total Other Income/Expenses | 2.06M | -4.73M | -4.75M | -2.33M | -3.90M | -3.48M | -365.00K | -1.08M |
| Income Before Tax | -26.67M | -36.17M | -44.18M | -28.72M | -33.51M | -23.72M | -20.79M | -24.07M |
| Income Before Tax Ratio | -11.04% | -38.70% | -145.99% | -112.00% | -141.95% | -182.18% | -270.54% | -387.58% |
| Income Tax Expense | -1.64M | 66.00K | 36.00K | 32.00K | 40.00K | 41.00K | 32.00K | 984.00K |
| Net Income | -25.03M | -36.23M | -44.22M | -28.75M | -33.55M | -23.76M | -20.82M | -24.07M |
| Net Income Ratio | -10.36% | -38.77% | -146.11% | -112.13% | -142.12% | -182.50% | -270.96% | -387.58% |
| EPS | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| EPS Diluted | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Weighted Avg Shares Out | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
| Weighted Avg Shares Out (Dil) | 32.52M | 29.56M | 27.62M | 24.70M | 14.20M | 19.25M | 14.48M | 14.48M |
Why Transmedics Group Stock Plummeted 21% This Week
Shares of Transmedics Group (TMDX 2.13%) sank over 20% this week, according to data from S&P Global Market Intelligence. The organ transplant disrupter announced a CFO transition and reduced the range for its full-year 2024 guidance, indicating slowing revenue growth.
TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024
TransMedics shares declined 60% from their August peak after a Q3 revenue miss, and more recently by slightly reduced revenue guidance range, surprising investors accustomed to beat-and-raise guidance. The company faces near-term challenges, but long-term growth prospects remain strong. The...
TMDX INVESTIGATION: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
SAN DIEGO , Dec. 3, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company as well...
Why TransMedics Stock Plummeted Today
Shares of leading organ transplant platform TransMedics (TMDX -15.43%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.
Zscaler, TransMedics Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday.
TransMedics Appoints Gerardo Hernandez as Chief Financial Officer and Provides Updated 2024 Financial Outlook
ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr.
Is TMDX Stock a Buy, Sell or Hold at a P/S Multiple of 5.02X?
TransMedics is facing a softness in demand for transplant services in the United States. Moreover, rising costs raise concern.
TransMedics to Host Investor & Analyst Day on December 10, 2024
ANDOVER, Mass. , Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an...
1 Top Growth Stock Down 56% to Buy After Its Recent Pullback
In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
2 Hypergrowth Stocks That Are Screaming Buys in November
2 Hypergrowth Stocks That Are Screaming Buys in November
Source: https://incomestatements.info
Category: Stock Reports